Adma Biologics (ADMA) Revenue (2011 - 2026)
Adma Biologics' (ADMA) quarterly Revenue came in at $139.2 million in Q4 2025, up 18.39% YoY from $117.5 million in Q4 2024, and up 3.68% on a QoQ basis from $134.2 million in Q3 2025.
Adma Biologics (ADMA) Revenue (2011 - 2026) Analysis & Trends
Adma Biologics (ADMA) has 14 years of Revenue data on file, last reported at $139.2 million in Q4 2025.
- Quarterly Revenue rose 18.39% year-over-year to $139.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $510.2 million (up 19.63% YoY) and the FY2025 annual result came in at $510.2 million, up 19.63% from the prior year.
- Revenue grew to $139.2 million in Q4 2025, from $134.2 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $139.2 million in Q4 2025 to a low of $16.0 million in Q1 2021.
- A 5-year average of $77.1 million and a median of $74.5 million in 2022 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue surged 320.63% — and 2023, when it declined 19.84%.
- Tracing ADMA's Revenue over 5 years: stood at $55.0 million in 2021, then declined by 9.12% to $50.0 million in 2022, then surged by 47.86% to $73.9 million in 2023, then soared by 59.06% to $117.5 million in 2024, then advanced by 18.39% to $139.2 million in 2025.
- The last three Revenue figures came in at $139.2 million (Q4 2025), $134.2 million (Q3 2025), and $122.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Adma Biologics | 2.13 Bn | 2.00 Bn | 86.28 Mn | 124.40 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 124.40 Mn |
| Dec 31, 2025 | 139.16 Mn |
| Sep 30, 2025 | 134.22 Mn |
| Jun 30, 2025 | 121.98 Mn |
| Mar 31, 2025 | 114.80 Mn |
| Dec 31, 2024 | 117.55 Mn |
| Sep 30, 2024 | 119.84 Mn |
| Jun 30, 2024 | 107.19 Mn |
| Mar 31, 2024 | 81.88 Mn |
| Dec 31, 2023 | 73.90 Mn |
| Sep 30, 2023 | 110.00 Mn |
| Jun 30, 2023 | 60.12 Mn |
| Mar 31, 2023 | 56.91 Mn |
| Dec 31, 2022 | 49.98 Mn |
| Sep 30, 2022 | 41.09 Mn |
| Jun 30, 2022 | 75.00 Mn |
| Mar 31, 2022 | 29.10 Mn |
| Dec 31, 2021 | 55.00 Mn |
| Sep 30, 2021 | 20.68 Mn |
| Jun 30, 2021 | 17.83 Mn |